Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Summary

This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK), activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia (AML).

Timeline

Start

2021-12-17

Primary completion

2022-07-21

Completion

2022-08-31

Outcome

Outcome not reported

Stopped: “Pivoting to an allogeneic version of this program currently in preclinical development.”

Drugs

Indications